U.S. Markets open in 8 hrs 14 mins
  • S&P Futures

    4,262.00
    +6.00 (+0.14%)
     
  • Dow Futures

    34,214.00
    +132.00 (+0.39%)
     
  • Nasdaq Futures

    14,367.00
    +12.75 (+0.09%)
     
  • Russell 2000 Futures

    2,335.30
    +4.10 (+0.18%)
     
  • Crude Oil

    73.34
    +0.04 (+0.05%)
     
  • Gold

    1,775.80
    -0.90 (-0.05%)
     
  • Silver

    26.07
    +0.02 (+0.06%)
     
  • EUR/USD

    1.1939
    +0.0004 (+0.0358%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    15.97
    -0.35 (-2.14%)
     
  • GBP/USD

    1.3922
    +0.0001 (+0.0056%)
     
  • USD/JPY

    110.8660
    +0.0310 (+0.0280%)
     
  • BTC-USD

    34,654.72
    +1,983.67 (+6.07%)
     
  • CMC Crypto 200

    833.51
    +46.89 (+5.96%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    29,091.84
    +216.61 (+0.75%)
     

Study Shows Medtronic's Cardiac Monitor Tops Standard Care for Atrial Fibrillation Detection

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Medtronic plc (NYSE: MDT) has announced clinical trial results from the STROKE atrial fibrillation (AF) trial assessing its Reveal LINQ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats compared to standard of care.

  • The findings were published in the Journal of the American Medical Association.

  • The study evaluated 496 patients, including 284 large vessel and 208 small vessel stroke patients.

  • At 12 months, AF was detected in 12.1% of patients in the ICM arm compared to 1.8% in the standard of care arm, equivalent to a greater than seven-fold increase in detecting AF in the ICM arm.

  • 78% of patients who had AF would have been missed if only monitored for 30 days. The median time to detection of AF was 99 days.

  • Rates of AF detection in the ICM arm were similar between patients with index strokes due to small vessel versus large vessel disease (12.6% compared to 11.7%, respectively).

  • At 12 months, 96.3% of first AF episodes were asymptomatic in the ICM arm.

  • The majority (55.5%) of patients with AF detected had an episode lasting more than one hour.

  • Separately, the company received FDA approval for its SenSight directional lead system used in deep brain stimulation (DBS) therapy.

  • The system is designed to combine directionality and sensing to allow physicians to deliver precise, patient-specific DBS therapy to treat symptoms associated with movement disorders.

  • The company touts SenSight as the first directional, sensing-enabled lead designed to improve the detection of local field potentials.

  • Price Action: MDT shares are up 0.21% at $124.11 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.